“…Administration of very high doses of ABA is well tolerated in mice without adverse effects (Li et al, 2011), which makes ABA treatments pharmacologically interesting. There are however reports that long-term ABA exposure might have adverse effects (Isik and Celik, 2015), which calls for caution. ABA treatment in humans and animal models has been suggested to be beneficial for type 2 diabetes (Guri et al, 2007; Bruzzone et al, 2015; Magnone et al, 2015), inflammatory bowel disease (IBD) (Guri et al, 2011; Viladomiu et al, 2013), atherosclerosis (Guri et al, 2010), systemic sclerosis (Bruzzone et al, 2012c), glioma (Zhou et al, 2016), depression (Qi et al, 2015b, 2016), and resistance against hepatitis C (Rakic et al, 2006), influenza (Hontecillas et al, 2013), malaria (Glennon et al, 2016), and mycobacteria (Clark et al, 2013).…”